Pulmocide Announces Presentation at 43rd Annual J.P. Morgan Healthcare Conference
LONDON, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Pulmocide Ltd., (“the Company”), a late-stage biopharmaceutical company developing inhaled opelconazole for patients suffering from serious acute and chronic respiratory diseases, today announced that Dan Burgess, …